Intra-Cellular Therapies Files Supplemental NDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder

MT NewswiresDec 3 23:59

Express News | Intra-Cellular Therapies Submits Supplemental New Drug Application (Snda) to FDA for Caplyta® (Lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

BreakingsDec 3 20:30

Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105

Futu NewsDec 2 21:32 · Ratings

Mizuho Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Announces Target Price $100

Futu NewsNov 30 01:32 · Ratings

RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)

TipRanksNov 28 09:47 · Ratings

Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM

Seeking AlphaNov 27 03:01